Thursday, April 25, 2013

Credit Suisse Q1 profit jumps to $1.37 billion

BASEL, Switzerland (AP) ? Swiss bank Credit Suisse Group reported Wednesday a huge jump in first-quarter profits compared with a year earlier, when it booked significant charges to its own debt.

Switzerland's second-biggest bank posted a profit of 1.3 billion Swiss francs ($1.37 billion), up sharply from the 44 million francs in the first quarter of 2012, when it booked a loss of 1.6 billion francs on its own outstanding debt and paid out higher bonuses. Net revenue rose 6 percent to 7.2 billion francs.

The figures show "positive momentum" based on a transformed business model, the bank said in its statement released before the opening of the Zurich exchange, where shares rose 1.4 percent to 26.82 francs in morning trading.

"The first quarter of 2013 shows that the strategic measures we have successfully implemented since mid-2011 are effective in bringing results to the bottom line on a consistent basis," Chief Executive Brady Dougan said.

The bank, based in Zurich, said the results for the January-March period showed "high returns, strong client franchises, reduced cost base and lower risk-weighted assets."

Like its cross-town competitor, UBS AG, which is Switzerland's biggest bank, Zurich-based Credit Suisse has been reducing its riskier investment banking activities at a time when Europe's economy is hurting.

The bank's quarterly report also showed further cutbacks in its staff, to 46,900 people, down 4 percent from 47,400 a year earlier.

Credit Suisse said Monday that it was selling its private equity business, Strategic Partners, which is based in Zurich, to New York-based Blackstone Group LP for an undisclosed amount. Strategic Partners manages $9 billion in assets and buys stakes in other private equity funds. The Zurich bank agreed last month to buy Morgan Stanley's wealth management unit, with $13 billion in assets under management, to expand in Europe, the Middle East and Africa.

Source: http://news.yahoo.com/credit-suisse-q1-profit-jumps-1-37-billion-083855334--finance.html

Bumbo recall USA Basketball taio cruz taio cruz Winter Olympics 2014 powerball numbers freddie mercury

Wednesday, April 24, 2013

Video reveals cancer cells' Achilles' heel

Video reveals cancer cells' Achilles' heel [ Back to EurekAlert! ] Public release date: 24-Apr-2013
[ | E-mail | Share Share ]

Contact: Morwenna Grills
Morwenna.Grills@manchester.ac.uk
44-161-275-2111
University of Manchester

Scientists from the Manchester Collaborative Centre for Inflammation Research (MCCIR) have discovered why a particular cancer drug is so effective at killing cells. Their findings could be used to aid the design of future cancer treatments.

Professor Daniel Davis and his team used high quality video imaging to investigate why the drug rituximab is so effective at killing cancerous B cells. It is widely used in the treatment of B cell malignancies, such as lymphoma and leukaemia - as well as in autoimmune diseases like rheumatoid arthritis.

Using high-powered laser-based microscopes, researchers made videos of the process by which rituximab binds to a diseased cell and then attracts white blood cells known as natural killer (NK) cells to attack. They discovered that rituximab tended to stick to one side of the cancer cell, forming a cap and drawing a number of proteins over to that side. It effectively created a front and back to the cell - with a cluster of protein molecules massed on one side.

But what surprised the scientists most was how this changed the effectiveness of natural killer cells in destroying these diseased cells. When the NK cell latched onto the rituximab cap on the B cell, it had an 80% success rate at killing the cell. In contrast, when the B cell lacked this cluster of proteins on one side, it was killed only 40% of the time.

Professor Davis says: "These results were really unexpected. It was only possible for us to unravel the mystery of why this drug was so effective, through the use of video microscopy. By watching what happened within the cells we could clearly identify just why rituximab is such an effective drug because it tended to reorganise the cancerous cell and make it especially prone to being killed."

He continues: "What our findings demonstrate is that this ability to polarise a cell by moving proteins within it should be taken into consideration when new antibodies are being tested as potential treatments for cancer cells. It appears that they can be up to twice as effective if they bind to a cell and reorganise it."

The findings from this study have been published online today on the website of the journal Blood. The research was carried out in collaboration with MedImmune, the global biologics research and development arm of AstraZeneca.

Commenting on the research Dr Matt Sleeman, Senior Director of Biology at MedImmune said: "Not only is this a great observation that can influence how we as a biotech company identify and design future therapies, it also shows the innovative 'out of the box' thinking that can be achieved by working in close partnership with academics at the top of their field. This unique partnership, bringing together industry and academia, demonstrates a real catalyst of scientific change within the UK, and I am excited by the potential of the MCCIR to bring further innovation that could ultimately bring benefit to patients."

Much of the research for this study was carried out during Professor Davis' time at Imperial College London. He will be continuing to use high quality video imaging at a microscopic level to investigate immunology at the MCCIR.

###

Professor Davis and MedImmune would like to acknowledge the funding they received from the Medical Research Council which helped make this study possible. The aim of the grant was to bring industry and academia closer together.


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Video reveals cancer cells' Achilles' heel [ Back to EurekAlert! ] Public release date: 24-Apr-2013
[ | E-mail | Share Share ]

Contact: Morwenna Grills
Morwenna.Grills@manchester.ac.uk
44-161-275-2111
University of Manchester

Scientists from the Manchester Collaborative Centre for Inflammation Research (MCCIR) have discovered why a particular cancer drug is so effective at killing cells. Their findings could be used to aid the design of future cancer treatments.

Professor Daniel Davis and his team used high quality video imaging to investigate why the drug rituximab is so effective at killing cancerous B cells. It is widely used in the treatment of B cell malignancies, such as lymphoma and leukaemia - as well as in autoimmune diseases like rheumatoid arthritis.

Using high-powered laser-based microscopes, researchers made videos of the process by which rituximab binds to a diseased cell and then attracts white blood cells known as natural killer (NK) cells to attack. They discovered that rituximab tended to stick to one side of the cancer cell, forming a cap and drawing a number of proteins over to that side. It effectively created a front and back to the cell - with a cluster of protein molecules massed on one side.

But what surprised the scientists most was how this changed the effectiveness of natural killer cells in destroying these diseased cells. When the NK cell latched onto the rituximab cap on the B cell, it had an 80% success rate at killing the cell. In contrast, when the B cell lacked this cluster of proteins on one side, it was killed only 40% of the time.

Professor Davis says: "These results were really unexpected. It was only possible for us to unravel the mystery of why this drug was so effective, through the use of video microscopy. By watching what happened within the cells we could clearly identify just why rituximab is such an effective drug because it tended to reorganise the cancerous cell and make it especially prone to being killed."

He continues: "What our findings demonstrate is that this ability to polarise a cell by moving proteins within it should be taken into consideration when new antibodies are being tested as potential treatments for cancer cells. It appears that they can be up to twice as effective if they bind to a cell and reorganise it."

The findings from this study have been published online today on the website of the journal Blood. The research was carried out in collaboration with MedImmune, the global biologics research and development arm of AstraZeneca.

Commenting on the research Dr Matt Sleeman, Senior Director of Biology at MedImmune said: "Not only is this a great observation that can influence how we as a biotech company identify and design future therapies, it also shows the innovative 'out of the box' thinking that can be achieved by working in close partnership with academics at the top of their field. This unique partnership, bringing together industry and academia, demonstrates a real catalyst of scientific change within the UK, and I am excited by the potential of the MCCIR to bring further innovation that could ultimately bring benefit to patients."

Much of the research for this study was carried out during Professor Davis' time at Imperial College London. He will be continuing to use high quality video imaging at a microscopic level to investigate immunology at the MCCIR.

###

Professor Davis and MedImmune would like to acknowledge the funding they received from the Medical Research Council which helped make this study possible. The aim of the grant was to bring industry and academia closer together.


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Source: http://www.eurekalert.org/pub_releases/2013-04/uom-vrc042413.php

At&t Wireless 9/11 Jerry Lawler andy murray Samsung Galaxy S3 bachelor pad bachelor pad

HR Interns at IBM Global Business Services | Ngcareers

?

IBM Global Business Services (GBS) is the world's largest consulting services organization. IBM GBS provides clients with business transformation and industry expertise, and the ability to translate that expertise into integrated, responsive, innovative business solutions and services that deliver bottom-line business value.

?

Job Title: HR Interns

Job ID: S_D-0560103

Job area: Human Resources (non consulting)

Business group IBM Sales & Distribution

?

Job description

Are you ready to work for a values-driven company that recognizes the unique contribution that every individual makes to an organization's success? As a Human Resources Professional, you'll design and execute a variety of HR programs or initiatives related to such areas as workplace climate and employee morale. You could also be the project leader for such projects at the business unit, site, country, region or geography level.As a Human Resources professional, you'll work across the HR community and the enterprise, using your expertise to collaborate with other functional areas and business leaders to drive initiatives in line with IBM's business and HR strategy.At IBM, our passion is progress. Join us.Interested in learning more about IBM? Check out the

?

Required

  • Bachelor's Degree
  • At least 1 year experience in Basic computer knowledge in MS Office (Word, Excel, Access)
  • At least 1 year experience in Human resources
  • English: Fluent

?

Preferred

  • Master's Degree
  • At least 2 years experience in Basic computer knowledge in MS Office (Word, Excel, Access)
  • At least 2 years experience in Human resources

?

IBM is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.

Source: http://ngcareers.com/2013/04/hr-interns-at-ibm-global-business-services

Kohls Black Friday www.walmart.com Macho Camacho Rise of the Guardians Pumpkin Pie Jack Taylor Apple Pie Recipe

Montana Democrat Baucus rules out 7th Senate term

Senate Finance Committee Chairman Sen. Max Baucus, D-Mont. leaves his committee office on Capitol Hill in Washington, Tuesday, April 23, 2013, saying that he was going to speak to the news media in his home state of Montana before discussing his retirement from the Senate. (AP Photo/J. Scott Applewhite)

Senate Finance Committee Chairman Sen. Max Baucus, D-Mont. leaves his committee office on Capitol Hill in Washington, Tuesday, April 23, 2013, saying that he was going to speak to the news media in his home state of Montana before discussing his retirement from the Senate. (AP Photo/J. Scott Applewhite)

Senate Finance Committee Chairman Sen. Max Baucus, D-Mont. leaves his committee office on Capitol Hill in Washington, Tuesday, April 23, 2013, saying that he was going to speak to the news media in his home state of Montana before discussing his retirement from the Senate. (AP Photo/J. Scott Applewhite)

FILE - In this Sept. 19, 2012 file photo, Senate Finance Committee Chairman Max Baucus, D-Mont. speaks reporters on Capitol Hill in Washington. According to Democratic officials: The six-term Democratic Sen. Max Baucus plans to retire. (AP Photo/J. Scott Applewhite, File)

FILE - In this April 17, 2013 file photo, Senate Finance Committee Chairman Sen. Max Baucus, D-Mont. speaks on Capitol Hill in Washington. According to Democratic officials: The six-term Democratic Sen. Max Baucus plans to retire. (AP Photo/J. Scott Applewhite, File)

Graphic profiles eight retiring U.S. senators

(AP) ? Senate Finance Committee Chairman Max Baucus of Montana announced plans Tuesday to retire at the end of his term after a career of enormous power and notable independence, producing both collaboration and conflict with fellow Democrats on major tax and health care legislation.

"I don't want to die here with my boots on. There is life beyond Congress," the 71-year-old Baucus said in a telephone interview with The Associated Press.

He became the eighth senator to announce retirement plans for 2014, and the sixth Democrat. One public poll recently suggested he would have faced a difficult challenge if he had sought a seventh term.

Republicans must gain six seats in 2014 to win a majority, and they said the retirement enhanced their prospects.

Yet Democrats were cheered when former Democratic Gov. Brian Schweitzer, who recently stepped down after two terms, swiftly expressed interest in the race.

In a brief statement, President Barack Obama said Baucus "has been a leader on a broad range of issues that touch the lives of Americans across the country."

Sen. Chuck Grassley, an Iowa Republican and Baucus' frequent legislative partner, was complimentary, too. "We ran the Finance Committee for 10 years together, and every bill except for three or four was bipartisan," he said in a statement. "The Senate will be worse off as a deliberative body when Senator Baucus leaves."

In a written statement, Baucus sketched an ambitious agenda for the rest of his term, topped by an overhaul of the tax code.

"Our country and our state face enormous challenges - rising debt, a dysfunctional tax code, threats to our outdoor heritage and the need for more good-paying jobs," he said, adding several Montana-specific priorities as well.

Baucus, a fifth-generation Montanan, was elected to the Senate in 1978 after two terms in the House. He became the top Democrat on the Finance Committee in early 2001. He has held the position ever since on the panel ? which has jurisdiction over taxes, Medicare, Medicaid, health care and trade ? as chairman when his party held a majority and as senior member of the minority when Republicans were in power.

The panel has a long tradition of bipartisanship, but Baucus ascended to power in an era of increasing partisanship in Congress.

Many Democrats were unhappy when he worked with Republicans to enact the tax cuts that President George W. Bush won in 2001. And then again in 2004 when Congress pushed through a GOP plan to create a new prescription drug benefit under Medicare, a measure that most Democrats opposed as a giveaway to the large drug companies.

Baucus stood with fellow Democrats in 2005 when Bush proposed legislation to partially privatize Social Security, an epic battle that ended in defeat for the president's effort.

He played a central role in the enactment of Obama's watershed health care legislation in 2010, although some inside his party complained that precious momentum was lost while he spent months on bipartisan negotiations that ultimately proved fruitless.

More recently, Baucus has expressed opposition to Democratic proposals to use an overhaul of the tax code as a means of raising additional revenue. He was one of four members of his party to oppose the budget the leadership brought to the floor with a requirement to that effect.

On other issues large and small, Baucus' voting record reflected his rural state.

Most recently, he voted against legislation that Obama backed to expand background checks for gun purchasers.

During the debate on the budget, he was the only Democrat to vote for a proposal to reopen White House tours. Most members of his party viewed the GOP measure as an attempt to embarrass Obama, but it would also have meant more money for clearing snow from the entrances to Yellowstone National Park, a portion of which is in Montana.

For more than a decade, Baucus has sought federal assistance for the residents of Libby, Mont., where asbestos contamination from a vermiculite mine has been linked to deaths and illnesses.

Sen. Jon Tester, D-Mont., said he learned of the retirement plans on Monday. He said Baucus told him he wanted to return to Montana, and noted that if he waited until the end of his next term he would be nearly 80.

Baucus, in the interview with the AP, said: "Been here 40 years. No regrets. It is time to do something different."

Maneuvering began almost instantly for the 2014 race.

"The opportunity to try and get the country moving again like we did in Montana, that's appealing," said Schweitzer, who outpolled Baucus in a hypothetical matchup in the recent poll. "I'm a fixer."

Possible Republican candidates include former Gov. Marc Racicot; former Rep. Denny Rehberg, who lost to Baucus in 1996 and to Tester last fall; former Rep. Rick Hill and Rep. Steve Daines. State Sen. Champ Edmunds of Missoula and former state Sen. Corey Stapleton, had already announced they would run against Baucus.

"Montana is a state where Republicans can and will do well," said Sen. Jerry Moran of Kansas, the GOP campaign committee chairman, pledging to provide the resources needed to turn the seat Republican.

The state twice voted against Obama in presidential races. Despite the president's presence on the ticket in 2012, Tester won a second term in a hotly contested challenge, and another Democrat, Steve Bullock, was elected governor.

Sen. Michael Bennet, D-Colo., who heads the Democratic Senatorial Campaign Committee, touted last year's re-election of Tester and said, "We will continue to invest all the resources necessary to hold this seat."

Democrats will be defending 21 seats next year, compared with 14 for Republicans.

Baucus joined Jay Rockefeller of West Virginia, Frank Lautenberg of New Jersey, Tim Johnson of South Dakota, Tom Harkin of Iowa and Carl Levin of Michigan in announcing his retirement plans.

Republicans Saxby Chambliss of Georgia and Mike Johanns of Nebraska also have decided not to seek re-election next year.

___

Gouras reported from Helena. Associated Press writers Matthew Brown in Billings, Andrew Taylor, Donna Cassata and Alan Fram in Washington and Carson Walker in Phoenix contributed to this report.

Associated Press

Source: http://hosted2.ap.org/APDEFAULT/89ae8247abe8493fae24405546e9a1aa/Article_2013-04-23-US-Baucus-Retirement/id-4c21e6984de34ef281040385b4dd4f97

Lark Voorhies Jennifer Livingston Orlando Cruz MLB Playoff Schedule arizona cardinals Big Bird Adam Greenberg

Tuesday, April 16, 2013

Research finds invasive kudzu bugs may pose greater threat than previously thought

Research finds invasive kudzu bugs may pose greater threat than previously thought

Tuesday, April 16, 2013

The invasive kudzu bug has the potential to be a major agricultural pest, causing significant damage to economically important soybean crops. Conventional wisdom has held that the insect pests will be limited to areas in the southern United States, but new research from North Carolina State University shows that they may be able to expand into other parts of the country.

Kudzu bugs (Megacopta cribraria) are native to Asia, and were first detected in the U.S. in Georgia in 2009. They have since expanded their territory as far north as Virginia. The bugs have an interesting life cycle, which has been thought to be a limiting factor on far they can spread.

Eggs laid in the spring hatch into a first generation, which we'll call "Generation A." The immature bugs of Generation A normally feed on kudzu plants until they reach adulthood, when they have been known to move into commercial soybean fields. These mature adults lay eggs that hatch into Generation B during the summer months. Generation B kudzu bugs can feed on soybean crops during both their immature and adult life stages, causing significant crop damage.

Because the immature Generation A kudzu bugs have only been seen to feed on kudzu, researchers thought that the pest would not be able to migrate to northern and western parts of the United States, where kudzu doesn't grow. But now it's not so clear.

Under controlled conditions in a greenhouse laboratory, researchers at NC State found that immature Generation A kudzu bugs were not limited to feeding on kudzu ? they were able to feed exclusively on soybeans, reach maturity and reproduce.

"Researchers began seeing some of this behavior in the wild in 2012 and, while those data aren't quite ready for publication, our lab work and the field observations indicate that kudzu bugs are potentially capable of spreading into any part of the U.S. where soybeans are grown. And soybeans are grown almost everywhere," says Dr. Dominic Reisig, an assistant professor of entomology at NC State and co-author of a paper on the research. "It also means that both annual generations of kudzu bugs could attack soybean crops in areas where the bug is already established, which would double the impact on farmers."

###

The paper, "First-Generation Megacopta cribraria (Hemiptera: Plataspidae) Can Develop on Soybeans," is a "rapid communication" article in the April issue of the Journal of Economic Entomology. Lead author of the paper is NC State doctoral student Alejandro Del Pozo-Valdivia. The research was supported by the United Soybean Board and the North Carolina Soybean Producers Association.

North Carolina State University: http://www.ncsu.edu

Thanks to North Carolina State University for this article.

This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.

This press release has been viewed 11 time(s).

Source: http://www.labspaces.net/127756/Research_finds_invasive_kudzu_bugs_may_pose_greater_threat_than_previously_thought

Aj Mccarron Girlfriend linkedin linkedin

Friday, April 12, 2013

'American Idol' Enters Uncharted Territory With Historic Elimination

Lazaro Arbos' ouster makes for the first all-female top five in the show's 12 seasons.
By Gil Kaufman


Lazaro Arbos of "American Idol"
Photo: Michael Becker/ Fox

Source: http://www.mtv.com/news/articles/1705475/american-idol-elimination-lazaro-arbos.jhtml

chris brown